Windlas Biotech (NSE:WINDLAS) Short-Term Debt: ₹299 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
87 GF Score
Price ₹880.50
GF Value ₹943.28
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Windlas Biotech Short-Term Debt?

Windlas Biotech NSE:WINDLAS +1.03% 87 Short-Term Debt is ₹299 Mil as of Mar. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 87/100 and a GF Value™ of ₹943.28 (Fairly Valued). The stock has 1 warning sign investors should review.

Windlas Biotech's Short-Term Debt for the quarter that ended in Mar. 2026 was ₹299 Mil.

Windlas Biotech's quarterly Short-Term Debt declined from Sep. 2025 (₹259 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹299 Mil).

Windlas Biotech's annual Short-Term Debt increased from Mar. 2024 (₹1 Mil) to Mar. 2025 (₹271 Mil) and increased from Mar. 2025 (₹271 Mil) to Mar. 2026 (₹299 Mil).

Windlas Biotech Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Windlas Biotech Short-Term Debt Related Terms

Windlas Biotech Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech Short-Term Debt Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial 56.77 3.35 1.09 271.17 298.75

Windlas Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 271.17 0.00 258.94 0.00 298.75
NSE:WINDLAS
87GF Score
Windlas Biotech Ltd NSE:WINDLAS
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ₹299 Mil mean?
Windlas Biotech (NSE:WINDLAS) has a Short-Term Debt of ₹299 Mil as of Mar. 2026.
Is Windlas Biotech's Short-Term Debt too high?
Windlas Biotech's current Short-Term Debt is ₹299 Mil. Overall, Windlas Biotech has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Short-Term Debt compare to ZTS and UTHR?
Windlas Biotech's Short-Term Debt of ₹299 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Windlas Biotech's current Short-Term Debt is ₹299 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹943.28, compared to a current price of ₹880.50 — trading 6.7% below its estimated fair value. The current Short-Term Debt is ₹299 Mil. Windlas Biotech's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Short-Term Debt is ₹299 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued. The current stock price of ₹880.50 is trading 6.7% below its estimated GF Value™ of ₹943.28. GuruFocus considers Windlas Biotech to be Fairly Valued.

Key valuation signals for NSE:WINDLAS:

  • Short-Term Debt: ₹299 Mil
  • GF Value™: ₹943.28 vs. price of ₹880.50 (6.7% below fair value)
  • GF Score™: 87/100 with 1 warning sign

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
87GF Score

Get the complete analysis for NSE:WINDLAS

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹880.50
Price
₹943.28
GF Value